Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16668985 | 0.88 | DUT (0.33) | ALDH1A1DUT | |
| SCHEMBL16669155 | 0.85 | ALDH1A1 (0.34) | ALDH1A1DUT | |
| SCHEMBL25288591 | 0.83 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL25278776 | 0.83 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL5970421 | 0.81 | DUT (0.34) | DUT | |
| SCHEMBL9842173 | 0.80 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL8014066 | 0.80 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL1930904 | 0.80 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL4844799 | 0.80 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL7562345 | 0.80 | ALDH1A1 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9315486-B2 | Therapeutic cyclopentanols, compositions thereof, and methods for use thereof | ALLERGAN, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150119454-A1 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2015-04-30 | — | — | US | disclosed |
| US-8680327-B2 | Methods for manufacturing tetranor-prostaglandin D, J, E, A and F metabolites | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120041229-A1 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119454-A1 | THERAPEUTIC CYCLOPENTANOLS, COMPOSITIONS THEREOF, AND METHODS FOR USE THEREOF | PTGIS, PDE3A, PTGIR | ALDH1A1 1422/4885DUT 1898/4885 |
| US-20120041229-A1 | METHODS FOR MANUFACTURING TETRANOR-PROSTAGLANDIN D, J, E, A AND F METABOLITES | PTGES, PTGDR, PTGIR | ALDH1A1 420/4885DUT 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.